Ranbaxy suffers at the US generic drug market

03 August, 2005

Ranbaxy, India's top drug maker suffered losses at the generic drug market in US. Its quarterly net profit fell to 49 percent making it a tough year for them. Though their sales rose to 7 percent, representatives of Ranbaxy Laboratories mentioned that the year ahead appears hard and highly competitive.

As Ranbaxy drugs are popular in US, they are also planning a copy of Pfizer;s cholesterol lowering drug Lipitor. Caverta is Ranbaxy; generic version of Viagra. It is produced in India and meets the same manufacturing standards as its original version of erectile dysfunction pill Viagra. Caverta is distributed in Europe and other countries as well.

To learn more visit:
http://asia.news.yahoo.com/050728/3/24puv.html